Trinity Delta Lighthouse: HUTCHMED
Trinity Delta view: The approval of the Orpathys/Tagrisso combination in China is an important element for revenue growth and sustained profitability. The smooth China approval, and near-term launch, in this broader NSCLC patient group should mean that Orpathys makes an increasingly meaningful contribution to domestic sales. This NSCLC indication also underpins the major global commercial opportunity for savolitinib, and recent data support the view that similar approvals will happen in global (ex-China) markets. Yet this is only one of many components supporting HUTCHMED’s investment case. In the near-term, the novel ATTC platform could be a significant new opportunity, with further details expected by early-2026, and surufatinib in pancreatic cancer could also provide a “wildcard” upside. Our valuation is $5.86bn/£4.69bn/HK$45.74bn, or $33.64/ADS and 538p/HK$52.48 per share.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.